'The urgency is increasing': Moderna spotlights vaccine, orphan drug programs, as it plots growth beyond Covid
At its R&D day two years ago, Moderna was still anxiously awaiting Phase III data on its Covid-19 vaccine. In a preview, CEO Stéphane Bancel talked about the next 12 months being “the biggest inflection point ever” if the shot got launched — as he laid out his new vision for a high-flying biotech vaulted three to four years ahead by the pandemic.
“We have 20 drugs in clinical development today,” Bancel told Endpoints News at the time. “Could we, in 18 months, 24 months from now have 40? 50? I think it’s possible.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.